ProfileGDS5678 / 1415901_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 85% 83% 86% 86% 85% 83% 83% 84% 83% 83% 86% 83% 82% 83% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.2633485
GSM967853U87-EV human glioblastoma xenograft - Control 26.1599383
GSM967854U87-EV human glioblastoma xenograft - Control 36.4675486
GSM967855U87-EV human glioblastoma xenograft - Control 46.7018986
GSM967856U87-EV human glioblastoma xenograft - Control 56.4702485
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.8980783
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.9681983
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.2543684
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.0556583
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.1366983
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.4412586
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.0943583
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.9549382
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.0721383